A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Foster, Graham R
  • Thompson, Alex J
  • Ruane, Peter J
  • Borgia, Sergio
  • Dore, Gregory
  • Workowski, Kimberly
  • Hyland, Robert H
  • Wang, Jing
  • Svarovskaia, Evguenia S
  • Stamm, Luisa M
  • Brainard, Diana M
  • Subramanian, Mani
  • McHutchison, John G
  • Berg, Thomas
  • Agarwal, Kosh
  • Conway, Brian
  • Feld, Jordan J
  • Willems, Bernard E
  • Roberts, Stuart K

publication date

  • October 1, 2016